USANA Health Sciences, Inc. (NYSE:USNA) Director Timothy E. Wood sold 426 shares of the firm’s stock in a transaction that occurred on Wednesday, July 29th. The shares were sold at an average price of $81.35, for a total value of $34,655.10. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Shares of NYSE USNA opened at $81.18 on Friday. The firm has a market cap of $1.71 billion, a P/E ratio of 16.08 and a beta of 0.90. USANA Health Sciences, Inc. has a 1-year low of $43.01 and a 1-year high of $92.26. The business’s 50 day moving average is $80.14 and its 200-day moving average is $75.27.

USANA Health Sciences (NYSE:USNA) last announced its earnings results on Tuesday, July 21st. The company reported $1.32 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.08 by $0.24. The company had revenue of $258.99 million for the quarter, compared to analyst estimates of $267.80 million. USANA Health Sciences had a return on equity of 32.87% and a net margin of 10.35%. During the same quarter last year, the company earned $0.91 earnings per share. On average, research analysts predict that USANA Health Sciences, Inc. will post 5.16 earnings per share for the current fiscal year.

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Fortis Advisors LLC increased its stake in shares of USANA Health Sciences by 3.9% during the first quarter. Fortis Advisors LLC now owns 3,383 shares of the company’s stock worth $195,000 after purchasing an additional 127 shares during the period. Schroder Investment Management Group increased its stake in USANA Health Sciences by 20.6% during the 1st quarter. Schroder Investment Management Group now owns 1,568 shares of the company’s stock worth $110,000 after acquiring an additional 268 shares during the period. Comerica Bank increased its stake in USANA Health Sciences by 3.0% during the 1st quarter. Comerica Bank now owns 12,216 shares of the company’s stock worth $1,023,000 after acquiring an additional 352 shares during the period. Janus Henderson Group PLC increased its stake in USANA Health Sciences by 3.3% during the 4th quarter. Janus Henderson Group PLC now owns 11,797 shares of the company’s stock worth $927,000 after acquiring an additional 377 shares during the period. Finally, Tower Research Capital LLC TRC bought a new position in USANA Health Sciences during the 1st quarter worth $27,000. Institutional investors own 53.19% of the company’s stock.

USNA has been the subject of a number of recent analyst reports. Tigress Financial reaffirmed a “buy” rating on shares of USANA Health Sciences in a research report on Tuesday, May 12th. Zacks Investment Research raised USANA Health Sciences from a “hold” rating to a “strong-buy” rating and set a $94.00 price objective for the company in a research report on Thursday, June 18th. Finally, ValuEngine cut USANA Health Sciences from a “hold” rating to a “sell” rating in a research report on Tuesday, July 7th. One research analyst has rated the stock with a sell rating, one has issued a hold rating, one has assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $79.50.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional and personal care products primarily to reduce the risk of chronic degenerative disease. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers comprising targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and foods that include low-glycemic meal replacement shakes, snack bars, and other related products, which provide macro-nutrition.

See Also: What is an overbought condition?

Insider Buying and Selling by Quarter for USANA Health Sciences (NYSE:USNA)

Receive News & Ratings for USANA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for USANA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.